Mankind Pharma Limited (MANKIND): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Mankind Pharma Limited, explained in plain English.

• ▪Mankind Pharma Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
• ▪MANKIND closed at ₹2,492.80 on 30 October 2026.
• ▪Over the past year the shares are up 1.9%, trading between ₹1,909.70 and ₹2,642.00.
• ▪Reported fundamentals show return on equity of 13.56%, a net margin of 14.58%, debt to equity of 30.36.
• ▪Our transparent MaxGrade checklist scores it B (70/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
• ▪Annualised volatility over the past year is 28.78% with a maximum drawdown of -21.22% and a beta of 0.65 against NIFTY 50.
• ▪Recent coverage: Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%
• ▪Recent coverage: Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
• ▪Recent coverage: Mankind Pharma Q2 PAT rises 37.7% on strong domestic chronic business

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 30 Oct 2026. Post-close session.